Antoxerene Closes $10 Million Deal with Juvenescence to Develop Small Molecule Drugs for Diseases of Aging
“There has been a lot of interest surrounding the therapeutic applications of senolytic drugs – compounds that clear toxic senescent cells – particularly with respect to age-associated disease” said
Commenting on this deal, CEO of Juvenescence
“We feel privileged to have received such staunch support for this program from its inception by our founding investors, including
Dr
About Antoxerene:
About Juvenescence:
Juvenescence believes that advances in science have made real the possibility of slowing, halting or potentially reversing some elements of ageing. Juvenescence believes that the resulting increase in life expectancy will have profound implications on all sectors and in particular healthcare, education, insurance and leisure.
About Ichor Therapeutics:
View source version on businesswire.com: https://www.businesswire.com/news/home/20180712005565/en/
Juvenescence
+1 315 677-8400
Source: Juvenescence
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News